Perinatal Viral Infections: Considering Achievements, Opportunities, and Paradoxes in ManagementHepatitis C in Pregnancy in the Era of Direct-acting Antiviral Treatment: Potential Benefits of Universal Screening and Antepartum TherapyBERNSTEIN, HELENE B. MD, PhD*; DUNKELBERG, JEFFREY C. MD, PhD†; LESLIE, KIMBERLY K. MD‡Author Information *Departments of Obstetrics and Gynecology and Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, New York †Department of Internal Medicine, Division of Gastroenterology and Hepatology ‡Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa The authors declare that they have nothing to disclose. Correspondence: Kimberly K. Leslie, MD, Department of Obstetrics and Gynecology, University of Iowa, 200 Hawkins Drive, 31140-A PFP, Iowa City, IA 52242. E-mail: [email protected] Clinical Obstetrics and Gynecology: March 2018 - Volume 61 - Issue 1 - p 146-156 doi: 10.1097/GRF.0000000000000345 Buy Metrics Abstract Hepatitis C in pregnancy is on the rise, and new direct-acting antiviral agents are available that cure the disease. Published recommendations need to be reviewed and clinically evaluated for the care of pregnant women who are at risk for or have chronic hepatitis C. Available evidence and some of the medical and ethical reasons to consider universal screening and antepartum therapy for hepatitis C during pregnancy are presented. Universal screening and proactive treatment during pregnancy is on the horizon, and these measures should be quickly evaluated for safety and implemented if appropriate. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.